Who are ONO-4059's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NALIRI, AD-2022, BAY86-4980, AD-2281, AD-2021, 1PC111.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ono-4059.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-21 · How we verify

ONO-4059 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ONO-4059 (ONO-4059) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K inhibitor. Area: Oncology.

phase 3 PI3K inhibitor PI3K (phosphoinositide 3-kinase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ONO-4059 (ONO-4059) — Ono Pharmaceutical Co. Ltd. ONO-4059 is a small-molecule inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ONO-4059 TARGET	ONO-4059	Ono Pharmaceutical Co. Ltd	phase 3	PI3K inhibitor	PI3K (phosphoinositide 3-kinase)
NALIRI	NALIRI	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	phase 3	PI3K inhibitor	PI3K
AD-2022	AD-2022	Addpharma Inc.	phase 3	PI3K inhibitor	PI3K
BAY86-4980	BAY86-4980	Bayer	phase 3	PI3K inhibitor	PI3K (phosphoinositide 3-kinase)
AD-2281	AD-2281	Addpharma Inc.	phase 3	PI3K inhibitor	PI3K
AD-2021	AD-2021	Addpharma Inc.	phase 3	PI3K inhibitor	PI3K
1PC111	1PC111	Orient Pharma Co., Ltd.	phase 3	PI3K inhibitor	PI3K

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K inhibitor class)

Addpharma Inc. · 4 drugs in this class
AstraZeneca · 3 drugs in this class
Bayer · 3 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 drugs in this class
InventisBio Co., Ltd · 2 drugs in this class
Orient Pharma Co., Ltd. · 2 drugs in this class
Applied Biology, Inc. · 1 drug in this class
Angitia Incorporated Limited · 1 drug in this class
Aevi Genomic Medicine, LLC, a Cerecor company · 1 drug in this class
BPGbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ONO-4059 — Competitive Intelligence Brief. https://druglandscape.com/ci/ono-4059. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab